Stocks · Healthcare · Biotechnology
BridgeBio Pharma, Inc. BBIO
$67.25 +0.51% Close, Oct 2, 2026 · NASDAQ · Market cap $13.17B
Low risk
Next earnings report: Oct 28, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $691.8M, up 193.4% from a year earlier, slowing from 355.2% a quarter earlier.
- Operating margin widened to -78.6% from -278.4% a year earlier.
- The stock is 25% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 7%
- Revenue growth, 3-year CAGRTop 9%
- Revenue growth accelerationBottom 2%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 20%
- Gross marginTop 16%
- Operating marginBottom 31%
- Accruals (lower is better)Top 12%
- Interest coverBottom 39%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 44%
- Free-cash-flow yieldTop 47%
- EBITDA / enterprise valueTop 50%
- Sales / enterprise valueBottom 19%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 37%
- 6-month returnBottom 34%
- 1-year return vs S&P 500Top 40%
- Distance from 52-week highTop 43%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 18%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 29%
- Upside to consensus price targetTop 48%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 12%
- Maximum drawdown, 3 yearsTop 23%
- Beta vs S&P 500 (lower is better)Top 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 355.2% | 193.4% | ↓ |
| Gross margin | 96.2% | 93.1% | ↓ |
| Operating margin | -278.4% | -78.6% | ↑ |
| FCF margin | -283.1% | -63.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 193.4% | 355.2% | ↓ | Top 7% |
| Gross margin | 93.1% | 96.2% | ↓ | Top 16% |
| Operating margin | -78.6% | -278.4% | ↑ | Bottom 31% |
| Net margin | -100.6% | -329.3% | ↑ | — |
| Free-cash-flow margin | -63.6% | -283.1% | ↑ | — |
| Return on invested capital | -61.8% | — | Bottom 20% | |
| Revenue growth, 3-year CAGR | 86.3% | — | Top 9% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -21.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 16.2%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +37.7 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -6.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 1.21%
- Shareholder yield
- 1.21%
- Share count change, 1 year
- +2.8%
- Share count change, 3-year CAGR
- +6.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 10, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -26.8%
- Average 2-day reaction, last 8
- +0.4%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $110.09
- Target vs current price
- +63.7%
- Analysts with a rating
- 27
- Share rating Buy or Strong Buy
- 89%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 10, 2026 | -35.5% | +0.2% | -5.5% | -11.4% | — |
| May 7, 2026 | -23.8% | -0.9% | +0.8% | -1.1% | +17.4% |
| Feb 24, 2026 | -40.2% | +0.6% | -3.5% | +2.5% | -2.8% |
| Oct 29, 2025 | -8.0% | +3.3% | -4.9% | +9.5% | +20.6% |
| Aug 5, 2025 | -14.5% | +3.1% | +1.0% | +4.7% | +35.1% |
| Apr 29, 2025 | +12.0% | +1.5% | +6.5% | -7.8% | +27.2% |
| Feb 20, 2025 | -20.2% | +1.4% | -7.8% | -7.0% | -7.0% |
| Nov 12, 2024 | +16.5% | -5.7% | -14.4% | +11.2% | +21.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.78 | -$0.58 | -35.5% | $243.7M |
| May 7, 2026 | -$0.84 | -$0.68 | -23.8% | $194.5M |
| Feb 24, 2026 | -$1.00 | -$0.71 | -40.2% | $154.2M |
| Oct 29, 2025 | -$0.95 | -$0.88 | -8.0% | $120.7M |
| Aug 5, 2025 | -$0.95 | -$0.83 | -14.5% | $110.6M |
| Apr 29, 2025 | -$0.88 | -$1.00 | +12.0% | $116.6M |
| Feb 20, 2025 | -$1.31 | -$1.09 | -20.2% | $5.9M |
| Nov 12, 2024 | -$0.86 | -$1.03 | +16.5% | $2.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 21.66× | — | — | Bottom 19% |
| Free-cash-flow yield | -3.34% | — | — | Top 47% |
| Earnings yield | -5.32% | — | — | Top 44% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.2%
- 200-day average slope (20 days)
- -0.3%
- Distance from 50-day average
- -11.9%
- Distance from 200-day average
- -8.6%
- RSI (14)
- 37.6
- Relative volume
- 0.90×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 31.5%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.96
- Correlation with S&P 500
- 0.33
- Current drawdown from 1-year high
- -25.4%
- Maximum drawdown, 3 years
- -49.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 8, 2021 | May 11, 2022 | -92.8% | 317 days | 894 days (Dec 3, 2025) |
| Jul 9, 2026 | Sep 25, 2026 | -27.3% | 55 days | Not yet recovered |
| Dec 31, 2020 | Jan 27, 2021 | -22.0% | 17 days | 8 days (Feb 8, 2021) |
| Jan 22, 2026 | Feb 5, 2026 | -20.3% | 10 days | 105 days (Jul 9, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $13.17B
- EPS, diluted (TTM)
- -$3.58
- Revenue (TTM)
- $691.8M
- 52-week range
- $51.85 – $93.42
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Gross profit | $66.6M | $74.2M | $6.9M | $218.0M | $473.8M |
| Operating income | -$576.6M | -$512.2M | -$607.4M | -$593.0M | -$569.1M |
| Net income | -$562.5M | -$481.2M | -$643.2M | -$535.8M | -$729.3M |
| EPS (diluted) | -$3.90 | -$3.35 | -$3.95 | -$2.88 | -$3.79 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $5.9M | $116.6M | $110.6M | $120.7M | $154.2M | $194.5M | $222.4M |
| Net income | -$162.0M | -$265.1M | -$167.4M | -$181.9M | -$182.7M | -$197.2M | -$164.0M | -$152.2M |
| EPS (diluted) | -$0.86 | -$1.40 | -$0.88 | -$0.95 | -$0.96 | -$1.00 | -$0.84 | -$0.78 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$497.9M | -$419.5M | -$527.7M | -$520.7M | -$445.9M |
| Capital expenditure | -$48.2M | -$6.3M | -$1.3M | -$933,000 | -$1.1M |
| Free cash flow | -$546.2M | -$425.8M | -$529.0M | -$521.7M | -$447.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$204.7M | $3.3M | $442.9M | $307.2M | -$14.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $720.2M
- Total assets
- $1.22B
- Total liabilities
- $3.72B
- Total debt
- $2.49B
- Net debt
- $1.82B
- Shareholders’ equity
- -$2.52B
As of Jun 30, 2026 (filed Aug 10, 2026).
Short interest
- Shares sold short
- 21,549,349
- Days to cover
- 10.54
- Change vs previous report
- -1.4%
FINRA short interest, settlement date Sep 15, 2026.